pojo-accessibility domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /nas/content/live/wwwclexiocom/wp-includes/functions.php on line 6121acf domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /nas/content/live/wwwclexiocom/wp-includes/functions.php on line 6121
Dr. Eran Nadav has been a board member at Clexio since September 2019. Dr. Nadav is an investor and a biopharma veteran. He has been with the investment firm TPG from 2007 to 2018, serving as Partner and Managing Director at the TPG Biotech fund in San Francisco. During his tenure at TPG, he led pharma and biotech deals across various geographies and stages of development.
Prior to TPG, Dr. Nadav was Business Development Director at Eisai in New Jersey, where he evaluated and negotiated licensing and acquisition deals. Previously, Dr. Nadav worked for JJDC, the venture capital subsidiary of Johnson & Johnson. Earlier, he worked for Neurim Pharmaceuticals in a product development role.
Dr. Nadav’s past and current investments and board roles include Carisma Therapeutics, Collegium Pharmaceutical (Nasdaq: COLL), Fusion Pharmaceuticals (Nasdaq: FUSN), JCR Pharmaceuticals (TSE: 4552), MacroGenics (Nasdaq: MGNX), Mey Eden, ShangPharma/ChemPartner, and Tevel Aerobotics Technologies. Dr. Nadav was the leading investor and Chairman of the Board of Ultragenyx Pharmaceutical (Nasdaq: RARE) and Trevi Therapeutics (Nasdaq: TRVI).
Dr. Nadav holds a Ph.D. in Biochemistry, an M.Sc. magna cum laude, a B.Sc. magna cum laude, and an MBA, all from Tel Aviv University.
